Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, announced participation in the Virtual 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, from 4:20 PM to 4:50 PM ET. The event will showcase Evolus' focus on delivering breakthrough products, including its FDA-approved neurotoxin, Jeuveau^®. Interested parties can access an audio webcast on the investor relations section of Evolus’ website, with a replay available for 90 days.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Event:			Virtual 11th Annual SVB Leerink Global Healthcare Conference
Date:			Wednesday, February 16, 2022
Time:			4:20pm – 4:50pm ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau^® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau^® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® is a registered trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220202005028/en/

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: david.erickson@evolus.com

Source: Evolus, Inc.

FAQ

What is the date and time of Evolus' participation in the SVB Leerink Global Healthcare Conference?

Evolus will participate in the SVB Leerink Global Healthcare Conference on February 16, 2022, from 4:20 PM to 4:50 PM ET.

Where can I find the audio webcast of Evolus' conference participation?

The audio webcast will be available on the investor relations section of Evolus’ website at www.evolus.com.

What product is Evolus known for that will be highlighted during the conference?

Evolus is known for Jeuveau^®, the first and only neurotoxin dedicated exclusively to aesthetics.

How long will the conference replay be available after the event?

A replay of the webcast will be available for 90 days after the conference.

What is the stock symbol for Evolus, Inc.?

The stock symbol for Evolus, Inc. is EOLS.